Human Biglycan(BGN) ELISA kit

Code CSB-EL002683HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details


This Human BGN ELISA Kit was designed for the quantitative measurement of Human BGN protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 0.312 ng/mL-20 ng/mL and the sensitivity is 0.078 ng/mL.

Target Name biglycan
Alternative Names BGN ELISA Kit; Biglycan ELISA Kit; Biglycan proteoglycan ELISA Kit; Bone/cartilage proteoglycan I ELISA Kit; Dermatan sulphate proteoglycan I ELISA Kit; DSPG1 ELISA Kit; PG S1 ELISA Kit; PG-S1 ELISA Kit; PGI ELISA Kit; PGS1_HUMAN ELISA Kit; SEMDX ELISA Kit; SLRR1A ELISA Kit; Small leucine rich protein 1A ELISA Kit
Abbreviation BGN
Uniprot No. P21810
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 0.312 ng/mL-20 ng/mL
Sensitivity 0.078 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Signal Transduction
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human BGN in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:5Average %89
Range %84-93
1:10Average %98
Range %84-102
1:20Average %84
Range %80-88
1:40Average %95
Range %90-100
The recovery of human BGN spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9389-98
EDTA plasma (n=4)105100-110
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
202.527 2.701 2.614 2.432
101.903 1.813 1.858 1.676
51.149 1.194 1.172 0.990
2.50.725 0.742 0.734 0.552
1.250.431 0.458 0.445 0.263
0.6250.350 0.341 0.346 0.164
0.3120.252 0.233 0.243 0.061
00.183 0.180 0.182
ELISA Data Analysis Watch ELISA data processing video & download Curve Expert if needed
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
May be involved in collagen fiber assembly.
Gene References into Functions
  1. The differential immunoexpression of perlecan and biglycan in these types of ameloblastomas suggests their participation in the developmental process of these tumors. PMID: 29921372
  2. TLR2 and BGN contribute to sterile inflammation and infertility in man. PMID: 27849015
  3. Results show that Biglycan expression was upregulated by DNA demethylation in tumour endothelial cells from myeloma. PMID: 27295191
  4. Elevated biglycan mRNA expression in adipose tissues of obese women PMID: 27465988
  5. sex-specific allele combinations of BGN, COL5A1, and DCN, as well as eight miRNA recognition sequences, were associated with altered susceptibility to anterior cruciate ligament ruptures PMID: 28927971
  6. high Bgn expression levels promote a more dense collagen architecture, leading to increased tissue stiffness. This increased tissue stiffness leads to higher integrin-beta1 expression on melanoma cells, which promotes their invasiveness. PMID: 28476030
  7. The expression of hBGN in the skeletal muscle of the treated mice was 1.34-fold higher than that of the native mouse Bgn (mBgn). The low transduction efficiency and improved motor functions suggest that biglycan expressed in a small number of muscle fibers was likely to have been secreted and anchored to the cell surface throughout the whole muscular fibers PMID: 27485975
  8. Results identified loss-of-function mutation in BGN gene in patients with an X-linked syndromic form of severe thoracic aortic aneurysms and dissections (TAAD) confirming BGN as causative gene in severe form of TAAD. PMID: 27632686
  9. After the first year of smoking abstinence the levels of BGN expression and carotid-femoral pulse wave velocity are significantly improved as compared to baseline. PMID: 28131044
  10. study reports a temporal relationship between altered placental biglycan expression and subsequent development of fetal growth restriction/small for gestational age. PMID: 28408374
  11. Quantitative polymerase chain reaction for messenger RNA expression from tissue specimens revealed significantly higher expression of Biglycan (p = 0.0008) and Lumican (p = 0.01) and lower expression of Decorin (p < 0.0001) in urothelial carcinoma of bladder PMID: 28459201
  12. Mutation in BGN gene is associated with X-Linked Spondyloepimetaphyseal Dysplasia. PMID: 27236923
  13. biglycan exerts an important role in cell proliferation, migration, invasion and apoptosis in colon cancer. PMID: 26459740
  14. BGN might play an important role on metastasis in human endometrial cancer and it might be a target marker for the molecular therapy of advanced and recurrence endometrial cancer. PMID: 26275380
  15. This study demonstrated that the small leucine-rich proteoglycan BGN accumulates in CADASIL and binds to NOTCH3. PMID: 25578324
  16. Biglycan may have a role in development of vascular damage in smokers PMID: 25463076
  17. BGN is a factor secreted by peritubular cells to modulate FGFR3c signaling and thus contributes to the regulation of spermatogonial maintenance PMID: 25260943
  18. The results suggest that regions within BGN is associated with ACL injury susceptibility and that genetic sequence variability within genes encoding proteoglycans may potentially modulate the ligament fibril properties. PMID: 24552666
  19. immunolocalization of decorin and biglycan in samples of first-trimester and term placentas, placenta accreta, invasive mole, and choriocarcinoma PMID: 24117774
  20. Biglycan modulates angiogenesis and bone formation during fracture healing. PMID: 24373744
  21. Data indicate that the biglycan (BGN) CC genotype was significantly over-represented in the control group versus the carpal tunnel syndrome (CTS) group. PMID: 25173489
  22. High expression of BGN in esophageal squamous cell carcinoma indicated aggressive tumor behaviors and predicted a worse clinical outcome. PMID: 24228112
  23. Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation. PMID: 24257755
  24. ADAMTS-4 and its substrate biglycan are involved in tubulogenesis by endothelial cells PMID: 24051360
  25. The concentration of aggrecan, biglycan, and decorin was determined in six regions of the human supraspinatus tendon. PMID: 22329809
  26. Molecular haplotypes within the BGN promoter may contribute to the molecular basis of interindividually different transcriptional BGN regulation, possibly modulating the predisposition to cardiovascular disease-related phenotypes. PMID: 23393390
  27. pancreatic adenocarcinoma patients who presented PG-I expression in the extracellular matrix had worse prognosis compared to those who did not PMID: 23007878
  28. Extracellular soluble biglycan induces the expression of BMP-2 and ALP in human aortic valve interstitial cells primarily via TLR2 and contributes to the proosteogenic effect of oxLDL. PMID: 22982459
  29. Up-regulation of biglycan was significantly correlated with poor tumor differentiation, lymph node metastasis, and distant metastasis in colorectal cancer. PMID: 21879307
  30. Bgn inhibits the major properties of HER-2/neu-transformed cells, which is inversely modulated by the PKC signaling cascade. PMID: 22582394
  31. Data show that granzyme B (GrB) liberated TGF-beta1 from substrates decorin, biglycan and betaglycan. PMID: 22479366
  32. These findings suggested that biglycan is a novel tumor endothelial cell marker and a target for anti-angiogenic therapy PMID: 22374465
  33. Biglycan demonstrated distinctive localization relative to nodules within calcified aortic valves. PMID: 21185747
  34. Biglycan enhances ovalbumin-specific cross-priming by over 80% to histocompatibility class I-restricted T cells in both a Toll-like receptor (TLR)2- and TLR4-pathway-dependent manner in transgenic mice. PMID: 22095710
  35. findings demonstrate that Akt is a downstream signalling component of TGF-beta-mediated biglycan core protein synthesis but not glycosaminoglycan chain hyperelongation in vascular smooth muscle PMID: 21913799
  36. Data revealed a strong induction of several genes encoding components of the extracellular matrix, such as collagens, COMP, IGFBP5 and biglycan. PMID: 21029365
  37. This study demonstrates that elevated expression of biglycan may play an important role in the development and progression of gastric cancer, and could be further evaluated as a biomarker for predication of a poor clinical outcome. PMID: 21998129
  38. Immunoprecipitation analysis revealed that biglycan interacts with both the canonical Wnt ligand Wnt3a and the Wnt coreceptor low-density lipoprotein receptor-related protein 6 (LRP6), possibly via the formation of a trimeric complex. PMID: 21969569
  39. Biglycan and decorin reduced the proliferation of pre-adipocytes, partly by induction of apoptosis. Furthermore, the anti-proliferative capabilities of decorin and biglycan were nullified with removal of GAG side-chains. PMID: 21702857
  40. Differential expression of 4 out of 5 genes related to estrogen metabolism and action (ESR1, ESR2, PGR and BGN) was confirmed in endometriosis. PMID: 21397694
  41. Biglycan impinges on the expression of total epidermal growth factor receptor and possibly, on the cell-surface expression of the receptors, playing a critical role in the regulation of chondrocyte and pericellular matrix homeostasis. PMID: 20367117
  42. expressed decreased in fetal growth restriction placentae PMID: 20591478
  43. Data show that biglycan (BGN) induces of phospholipid transfer protein (PLTP) in aortic valve interstitial cells via stimulation of Toll-like receptor 2, so increased BGN in stenotic valves contributes to the production of PLTP via TLR 2. PMID: 20382708
  44. study shows (1) a detailed description of ectopic ossification (EO) formed by Bgn, Fmod or combined depletion, (2) the role of exercise in modulating EO and (3) that Bgn and Fmod are critical in controlling motor function. PMID: 19422643
  45. has two GAG chains and affinity to collagen PMID: 11979972
  46. BGN expression is regulated by TGFbeta1 in pancreatic tumor cells and has a role in controlling cell growth PMID: 12140283
  47. isoforms of biglycan have a smaller core protein substituted with smaller glycosaminoglycan chains, are N-glycosylated, which demonstrates that a lack in N-glycosylation is not the reason for a smaller core. PMID: 12153565
  48. biglycan showed a unique ability to organize collagen VI into extensive hexagonal-like networks over a time period of only a few minutes PMID: 12354766
  49. regulation of gene expression by transforming growth factor-beta requires MKK6-p38 mitogen-activated protein kinase signaling downstream of Smad signaling PMID: 12538652
  50. Biglycan may be involved in vascular smooth muscle growth & migration through cdk2- & p27-dependent pathways. Changes in its expression may affect arterial susceptibility to vascular injury, & may play a direct role in pathogenesis of vascular lesions. PMID: 15031262

Show More

Hide All

Involvement in disease Meester-Loeys syndrome (MRLS); Spondyloepimetaphyseal dysplasia, X-linked (SEMDX)
Subcellular Location Secreted, extracellular space, extracellular matrix.
Protein Families Small leucine-rich proteoglycan (SLRP) family, SLRP class I subfamily
Tissue Specificity Found in several connective tissues, especially in articular cartilages.
Database Links

HGNC: 1044

OMIM: 300106

KEGG: hsa:633

STRING: 9606.ENSP00000327336

UniGene: Hs.821

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1